Injury Recovery Applications

Introduction

BPC-157 and TB-500 are the peptides lifters and athletes mention most for injury recovery. This page sorts what users report by injury type. The evidence is mostly animal work: a 2025 systematic review of BPC-157 found 36 studies, 35 of them preclinical, and as of October 2026 FDA says it has no human exposure data for the TB-500 fragment. For how the two differ, see how BPC-157 and TB-500 work.

Tendon Injuries

Tendinitis/Tendinopathy

• Peptide Choice: Users most often pick BPC-157 for tendons
• Reported protocol: Commonly 250-500 mcg BPC-157 per day near the site, in one or two doses
• Duration: 4-8 weeks in user reports
• Reported response: Some users describe less pain within 2-4 weeks; others notice nothing

Tendon Tears (Partial)

• Reported protocol: BPC-157 and TB-500 together
• BPC-157: Some users report 500 mcg twice daily near the injury
• TB-500: Vendor guidance describes 2.5 mg twice weekly as "loading"
• Duration: 6-12 weeks in user reports
• Note: Severe tears require medical evaluation

Muscle Injuries

Muscle Strains

• Primary Peptide: Many users favor TB-500 for muscle; no study has compared the two
• Reported protocol: TB-500 2.5 mg twice weekly plus BPC-157 250 mcg twice daily
• Duration: 4-8 weeks in user reports
• Adjuncts: Appropriate rest, gradual return to training

Muscle Tears

• Severity Assessment: Medical imaging recommended
• Reported protocol: The same combination, often at the top of the ranges above
• Duration: 8-12 weeks or longer in user reports
• Return to Training: Gradual, based on healing progress

Joint Issues

Ligament Sprains

• Peptide Selection: Users often combine both
• BPC-157: Linked in animal studies to fibroblast activity and new blood vessel growth
• TB-500: Full-length thymosin beta-4 drives cell migration in lab studies; TB-500 is only a fragment of it
• Reported protocol: The combined amounts above for 6-8 weeks

Cartilage Issues

• Limited Evidence: Peptides are least studied for cartilage
• Human data: In one uncontrolled knee series, 14 of 16 patients reported pain relief after BPC-157 alone or with thymosin beta-4; pain relief isn't cartilage repair
• Expectations: Set realistic goals, cartilage heals slowly

Soft Tissue Recovery

Post-Surgical Recovery

• Timing: Users typically describe starting after the initial healing phase
• Consult Surgeon: Important before adding peptides
• Reported protocol: The combined approach, 8-12 weeks

Chronic Injuries

• Approach: Users describe longer runs
• Patience: Many users report no clear change at 3-6 weeks
• Rehab: Users who improve usually did rehab too, so the peptide's share is unclear

Protocol Comparison by Injury

These are patterns users describe, not tested protocols. For the doses behind them, see dosing protocols for BPC-157 and TB-500.

Important Considerations

• Peptides don't replace proper rehabilitation
• Continuing to train through injury worsens outcomes
• Research-use vials aren't regulated, so product quality varies
• Safety data are minimal: a 2025 IV pilot in 2 adults (up to 20 mg BPC-157) reported no side effects
• Tested athletes face anti-doping rules for both; see legal status and regulatory considerations

What we still don't know

As of October 2026, no controlled human trial of either peptide for a musculoskeletal injury has published results; a 20-patient BPC-157 pilot after rotator cuff repair is registered to start in January 2027. Nobody has tested whether injecting near the injury beats systemic use, or whether the pair beats either alone. Users often can't tell whether a "TB-500" vial holds the fragment or full thymosin beta-4.